Last month the president of the United States signed the Inflation Reduction Act. This act has beneficial effects over Medicare prescription drugs coverage and also has some other positive effects for the Medicare recipients. Some of these benefits might be effective in a few years, but it’s good to see that they are looking for different alternatives to protect us making health care reachable for people despite the inflation increases.
The Act states that the Secretary of Health and Human Services will negotiate the prices for some drugs that are manufactured by only one lab and that are covered by Medicare Part B and Part D in order to reduce the price that Medicare recipients pay for these drugs.
One of the most positive impacts is that this Act states that it reduces the Part D Out Of the Pocket (OOP) spending at the catastrophic threshold from $7,050 from this year to $2,000 in 2025.
Here is a resume by year of what we can expect:
